 |
|
|
|
 |
|
|
| Article 1 to 10 out of 107 concerning Crucell N.V.
|
-
Crucell's Supervisory Board Nominates Mr. W. Burns, Mr. J. Shannon and Mr. G. Siber as New Board Members
(16 Mar 2010)
Crucell N.V. announced the nomination of Mr. William (Bill) Burns, Mr. James Shannon and Mr. George Siber to join its Supervisory Board. The Supervisory Board of Crucell has nominated Mr. Burns, Mr. Shannon and Mr. Siber as new members of the ...
-
Crucell HIV Vaccine: Promising Preliminary Results Phase I Study
(23 Oct 2009)
Crucell N.V. announced that preliminary results of the Phase I study of its HIV vaccine were presented at La Conférence AIDS Vaccine 2009 in Paris, France. The presentation was given by Dr Dan H. Barouch, MD, PhD, Associate Professor of Medicine, ...
-
Crucell Rabies Monoclonal Antibody Combination: Positive Results Philippines Phase II Study Presented at RITA Conference
(22 Oct 2009)
Crucell N.V. announced that detailed results of the Phase II Philippines study of its rabies monoclonal antibody combination (CL 184) were presented at the XX Rabies in the Americas (RITA) Conference in Quebec, Canada. The presentation was given by ...
-
Crucell Strengthens its Vaccine Sales in the UK with a Dedicated Marketing and Sales Organization
(01 Oct 2009)
Crucell N.V. announced the launch of its own dedicated marketing and sales organization in the United Kingdom by acquiring an experienced team, to further strengthen its vaccine sales position in one of the largest vaccine markets in ...
-
Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Therapies for Influenza Prevention and Treatment
(30 Sep 2009)
Johnson & Johnson and Crucell N.V. announced that Johnson & Johnson, through its subsidiary Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Crucell have entered into a strategic collaboration focusing on the discovery, development and ...
-
PATH Malaria Vaccine Initiative and Crucell to test new malaria vaccine approach
(30 Jul 2009)
The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), and Crucell N.V. announced a collaboration to accelerate development of a promising type ...
-
Crucell Announces Positive Results of Phase II Rabies Monoclonal Antibody Combination Clinical Study in Philippines
(25 Jun 2009)
Crucell N.V. announced the results of a second phase II clinical study of its investigational rabies monoclonal antibody combination, which started in May 2008 in the Philippines. Crucell has a collaboration and commercialization agreement with ...
-
Crucell's Revolutionary Antibody for Universal Therapy Against Flu
(03 Mar 2009)
Crucell N.V. announced that the journal Science published a study showing why Crucell's novel anti-influenza antibody is so effective against such a broad range of influenza virus subtypes. These characteristics make the Crucell antibody CR6261 a ...
-
DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6 Cell Line Proteins
(11 Feb 2009)
DSM Biologics and Crucell N.V. announced that they have entered into an agreement with Bioceros B.V. to join their Vendor Network. Under the terms of the agreement, Bioceros will be a pre-approved cell line generation partner for licensees of the ...
-
Crucell and Wyeth in discussion on a combination of the two companies
(09 Jan 2009)
Crucell N.V. confirmed that it is in friendly discussions with Wyeth that may lead to a combination of the two companies. These discussions are at a preliminary stage and there is no certainty that they will result in a transaction. An update will ...
Additional information
Crucell N.V.
Leiden, Netherlands
Company
|
|
|
|
|
|
Top
